| abstract |
The invention belongs to the field of immunotherapy, it relates to new ligands for the CD4 molecule, mutant Fab fragments of the anti-CD4 antibody, 13B8.2 binding the CD4 molecule and comprising a mutation of at least one residue in a position located in the VH variable domain of the heavy chain and / or in a position located in the Vκ variable domain of the light chain. The invention also relates to pharmaceutical compositions containing these ligands for the treatment of pathologies in which the CD4 molecule is involved. |